RxDoctor Payments Data

Jason Fleming, MD

Cardiovascular Disease · Indianapolis, INNPI 1053376640

Payments from drug & device makers

$2,750in general payments, 2019–2025

Across 184 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$679
  • Pfizer$491
  • Amgen$270
  • Novo Nordisk$228
  • Novartis$217
  • AstraZeneca$205
  • plus $660 from 16 others

What the payments were for

  • Food & beverage$2,743100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,750 in reported general payments places this provider in the 45th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$141,016
Medicare patients
1,361
Services billed
2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban563$735,000
XareltoRivaroxaban191$260,843
EntrestoSacubitril/Valsartan136$195,718
Repatha SureclickEvolocumab66$80,725
JardianceEmpagliflozin29$35,457
VascepaIcosapent Ethyl25$15,665
Metoprolol Succinate643$10,154
BrilintaTicagrelor18$10,027
Diltiazem 24hr Er (Cd)Diltiazem Hcl215$8,540
Ranolazine ErRanolazine51$6,920
Ezetimibe338$6,838
Atorvastatin Calcium693$6,819
Rosuvastatin Calcium373$4,569
Losartan Potassium491$4,175
Carvedilol542$4,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$491$735,000563 claims
Johnson & JohnsonXarelto$679$260,843191 claims
NovartisEntresto$217$195,718136 claims
Boehringer IngelheimJardiance$63$35,45729 claims
AstraZenecaBrilinta$205$10,02718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →